Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations
Rhea-AI Summary
Hemostemix (OTCQB: HMTXF) appointed Shaune Harding, OStJ, RN (non-practicing) as Director of Patient Care & Clinical Operations effective December 4, 2025. Harding will oversee patient onboarding, comprehensive medical-records transfer, multi-year health-journey mapping, continuous wearable-data monitoring (e.g., Fitbit Sense 2), monthly follow-ups, and adverse-event tracking with escalation and formal reporting.
The role covers patient programs in The Bahamas, Florida, and Canada and is described as supporting long-term continuity of care, enabling patient data capture to advance regulatory approval of ACP-01/VesCell.
Positive
- Experienced clinical lead with 30+ years of hands-on care
- Role covers patient programs in The Bahamas, Florida, and Canada
- Wearable data capture (Fitbit Sense 2) integrated into monitoring
- Adds monthly follow-up and formal adverse-event reporting
Negative
- None.
News Market Reaction – HMTXF
In the trading session that priced this news, HMTXF gained 9.95%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 03 | Conference presentation | Positive | -8.9% | Showcased ACP-01/VesCell limb salvage and ulcer reduction data at wound meeting. |
| Dec 02 | Conference & financing | Positive | -3.2% | Announced DFCon participation plus TSXV-approved private placement with warrants. |
| Nov 26 | Practice acquisition | Positive | -3.2% | Binding LOI to acquire two cardiology practices and extend financing timeline. |
| Nov 18 | Conference data update | Positive | +6.6% | Reported Phase II wound-healing data and market size at Florida conference. |
| Nov 13 | Clinical data presentation | Positive | -3.2% | Presented ACP-01 safety, efficacy signals, and Florida access pathway at grand rounds. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical, conference, and transaction news often saw negative next-day price reactions, with only one of five events aligning positively with the news tone.
Over the last month, Hemostemix has highlighted ACP-01/VesCell clinical data, conference presentations, and strategic steps to commercialize its therapy. Events on Nov 13, Nov 18, and Dec 3 emphasized safety, efficacy, and wound-healing outcomes. On Nov 26 the company advanced a roll-up of cardiology practices alongside financing, and on Dec 2 it closed a private placement. Despite broadly positive themes, four of these five news days saw negative 24-hour price reactions.
Key Terms
hipaa-compliant regulatory
autologous stem cell therapeutics medical
ischemic diseases medical
adverse event medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Calgary, Alberta--(Newsfile Corp. - December 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), a leader in autologous stem cell therapeutics for ischemic diseases, is pleased to announce the appointment of Shaune Harding, OStJ, RN non-practicing, as Director of Patient Care & Clinical Operations. In this senior clinical role, Ms. Harding will oversee:
- On-boarding of all new patients entering Hemostemix treatment programs;
- Comprehensive medical records review and HIPAA-compliant transfer of patient records to the treating physician team;
- Patient health-journey mapping, from initial assessment through treatment and multi-year follow-up;
- Continuous patient data monitoring, including heart rate, activity, exercise, and sleep metrics captured through approved wearable devices such as Fitbit Sense 2;
- Monthly follow-up meetings to support goal setting, healthcare journey adherence, and improvements in functional status;
- Adverse event monitoring, documentation, and reporting, including:
- Real-time tracking of patient-reported issues;
- Immediate escalation protocols to the treating physician;
- Formal reporting to Hemostemix's clinical operations team and regulators.
- Ensuring compliance with regulatory, clinical, and safety obligations.
Ms. Harding brings more than three decades of patient-hands-on clinical and management experience to her role, which will be leveraged it to advance Hemostemix's personalized care experience in The Bahamas, Florida, and Canada. This integrated role strengthens Hemostemix's hands-on, patient-centric healthcare model. It ensures long-term continuity of care for all who are treated with VesCell. Equally important, it enables patient data capture, which will be used to advance regulatory approval of ACP-01.
"I've known Shaune since 1967," said Thomas Smeenk, President & CEO of Hemostemix. "Shaune has always been one of the best-hearted friends anyone could have. Hemostemix's patients are going to love working with her, as she will help them get assessed, onboard, treated, and followed-up monthly. Shaune is the perfect person to guide patients throughout their health journey, and I'm thrilled to welcome her to head our patient care team," Smeenk said.
ABOUT HEMOSTEMIX
Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in eleven peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of
For further information, please contact: Thomas Smeenk, President, CEO EM: tsmeenk@hemostemix.com / PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the Phase I clinical trial of ACP-01 as a treatment for Vascular Dementia, and the treatment of pain related to CLTI in Florida and other jurisdictions related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia with Angiogenic Cell Precursors (ACP-01) in furtherance of sales of VesCell™ (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276823